Funding for this research was provided by:
Canadian Institutes of Health Research
Novartis Pharmaceuticals Canada (In kind)
Fondation de l'Hôpital Sainte-Justine
Received: 29 October 2019
Accepted: 16 March 2020
First Online: 17 April 2020
Change Date: 20 May 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: This trial was approved by the Sainte-Justine Hospital’s Research Ethics Board. All participants will provide informed consent upon recruitment.
: Not applicable.
: The authors declare no conflict of interest related to the study. KS reports personal fees from Novartis outside the submitted work. ADR reports grants from Merk and ALK outside the submitted work. PB reports personal fees from Novartis, Pfizer, Sanofi, ALK and Aralez, as well as grants from DBV technologies, Regeneron and Sanofi outside the submitted work.